Apelian David 4
4 · Eiger BioPharmaceuticals, Inc. · Filed Oct 6, 2017
Insider Transaction Report
Form 4
Apelian David
Director
Transactions
- Award
Stock Option (Right to Buy)
2017-09-28+25,000→ 25,000 totalExercise: $10.75Exp: 2027-09-28→ Common Stock (25,000 underlying)
Footnotes (1)
- [F1]The option vests in equal monthly installments over 36 months measured from June 14, 2017 subject to Reporting Person's continuous service status as of each such date.